Nutrition Intervention for Pancreatic Cancer with Encala®
This study is testing a special nutritional supplement called Encala® for people with pancreatic cancer (Pancreatic Ductal Adenocarcinoma or Pancreatic Neuroendocrine Tumor). Many pancreatic cancer patients have trouble absorbing fats, which can lead to weight loss and other issues. Encala® is a powder taken by mouth or feeding tube that aims to improve fat absorption without needing the usual digestive enzymes. Researchers want to see if it's practical to use and how well people stick with it over 8 weeks. They will also look at how it affects your stomach and gut symptoms. The study is currently unclear on its recruitment status and plans to enroll about 18 adults who are at least 18 years old and have a life expectancy of 4 months or more.
- Study design
- This is a single-arm pilot study, meaning all 18 participants will receive the Encala® intervention. It is designed to evaluate the feasibility, tolerance, and safety of the intervention.
- What's involved
- You would take 4-5 doses of Encala® daily for 8 weeks. You will have assessments at the start of the study, at 4 weeks, and at 8 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will follow participants from enrollment to the end of the intervention at 8 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Nutrition Intervention for Pancreatic Cancer
At a glance
Conditions
NCT07554560
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Children's Hospital of Philadelphia
Philadelphia, Pennsylvaniastudy coordinator listed
Recruiting
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvaniastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Virginia A Stallings, MD · PRINCIPAL_INVESTIGATOR · Children's Hospital of Philadelphia
- Jefferson N Brownell, MD · PRINCIPAL_INVESTIGATOR · Children's Hospital of Philadelphia
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Feasibility of Encala Intervention ( Enrollment Rate )From enrollment to end of intervention at 8 weeks
Feasibility will be evaluated as a measure, including enrollment rate, retention rate, visit completion, and product adherence. Enrollment rate is defined as the proportion of eligible participants enrolled.
- Change in PROMIS Gastrointestinal Symptom ScoreBaseline to Week 8
The Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scale measures gastrointestinal symptom severity across domains such as diarrhea, belly pain, constipation, nausea, and vomiting. 'Never/Not all' indicates improved/better gastrointestinal symptoms, while "Always/Very bad " indicates worse gastrointestinal symptoms.
- Feasibility of Encala Intervention ( Retention Rate )Baseline to Week 8
Retention rate is defined as the proportion of participants completing the study.
- Feasibility of Encala Intervention ( Visit Completion)Baseline to Visit 8
Visit completion is defined as the proportion of scheduled visits completed
- Feasibility of Encala Intervention ( Product Adherence )Baseline to Visit 8
Product adherence is defined as the proportion of prescribed doses consumed based on daily logs and returned product records.